In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Prestige Consumer Healthcare Inc.

https://www.prestigebrands.com/

Latest From Prestige Consumer Healthcare Inc.

Prestige Consumer Adapts Online Messaging For Pandemic-Shifted Shopping Paradigm

Prestige Consumer boosted marketing spending 17% in its latest quarter to $40.2m with strategies including viral videos and adding messages to branded e-commerce pages to attract online shoppers. Consumer purchases of products rose 7% in the January-March period.

E-Commerce Sales & Earnings

Prestige Consumer Healthcare Grows International Sales 8%, Citing Hydralyte Expansion

Prestige Consumer Healthcare’s Hydralyte sales grew in excess of 20% fiscal year-to-date in key market Australia, reflecting PCH’s work to expand the brand’s appeal from a vomiting and diarrhea treatment to a sports and general hydration drink. Hydralyte is PCH’s biggest brand in Australia where the name is “synonymous with oral hydration,” company leadership says.

Health Sales & Earnings

OTC Decisions Tracker: Dr Reddys NRT Lozenge Approved, Prilosec OTC And Monistat Packaging Revised

HBW Insight introduces an ongoing feature with information on decisions by FDA on NDAs and ANDA for nonprescription drugs and on sNDAs for label and package changes for approved OTC products. Dr Reddys Laboratories' clearance to launch OTC nicotine replacement therapy lozenges in the US and revisions to Prilosec OTC and Monistat packaging were among FDA's s OTC-related decisions in January.

OTC Drugs FDA

Prestige Sales Flat, Net Income Up

Net income for its FY 2020 second quarter grew 8.1% to $33.3m and diluted earnings per share were up to 65 cents from 59 cents in the year-ago period.

OTC Drugs Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Prestige Brands, Inc.
UsernamePublicRestriction

Register